Literature DB >> 9260012

Postoperative elevation of creatine kinase (CK-MB): does it contribute to diagnosis of myocardial infarction?

E Chedrawy1, R Hall, V Nedelcu.   

Abstract

PURPOSE: This retrospective study sought to determine the benefit of measurement of changes in plasma creatine kinase-myocardial band (CK-MB) levels in elective postoperative high risk surgical patients beyond that obtained from the surface 12 lead ECG.
METHODS: The charts of 111 patients admitted to the surgical intensive care unit (SICU) of a tertiary level university teaching hospital were reviewed. They were screened using predetermined definitions of myocardial infarction (MI) (as reflected by changes in the 12 lead surface ECG (Minnesota code) or elevations in CK-MB) for complications such as pulmonary oedema, congestive heart failure, arrhythmias, or cardiogenic shock. Four groups were identified based on changes in the ECG indicative of MI (Present-ECG+ or Absent-ECG-) and elevations of CK-MB (Present-CKMB+ or Absent-CKMB-) and compared for the incidence of complications.
RESULTS: No patient with ECG- findings had a complication. Fifteen patients with ECG+ findings were identified and all had complications. Fourteen of these patients had CKMB+ results. In contrast, 29 patients with CKMB+ results alone (i.e., ECG-) had no complications.
CONCLUSION: Clinically important (i.e., requiring therapeutic intervention) postoperative myocardial infarction was detected by ECG changes. The benefit of determining changes in CK-MB was minimal from a therapeutic perspective.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9260012     DOI: 10.1007/bf03013161

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  1 in total

1.  Clinical and biochemical prediction of early fatal outcome following hip fracture in the elderly.

Authors:  Ove Talsnes; Fredrik Hjelmstedt; Ola E Dahl; Are Hugo Pripp; Olav Reikerås
Journal:  Int Orthop       Date:  2010-11-16       Impact factor: 3.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.